Inpalix (Paliperidone)

Paliperidone works by blocking dopamine D2 receptors and serotonin 5‑HT2A receptors in the brain, which reduces dopaminergic overactivity linked to psychosis and modulates serotonergic pathways that influence mood. It also has partial agonist activity at 5‑HT1A receptors and modest inhibition of norepinephrine reuptake, contributing to its antipsychotic and mood‑stabilizing effects.

The appropriate dose of Inpalix is determined individually by the prescribing clinician based on the patient’s clinical condition, response, and tolerability. Dosage adjustments may be made during treatment, and patients should follow the specific instructions provided by their healthcare provider and the product label.

Safety of paliperidone in pregnancy and lactation has not been fully established. The drug should only be used if the potential benefit justifies the potential risk to the fetus or infant, and the decision must be made by the prescribing physician in consultation with the patient.

To request Inpalix, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Inpalix (paliperidone) is the primary active metabolite of risperidone and shares a similar receptor profile, but it offers once‑daily dosing and a longer half‑life, which can improve adherence. Compared with older typical antipsychotics, it has a lower risk of extrapyramidal symptoms but may cause metabolic changes and prolactin elevation.

Inpalix tablets should be stored at ambient temperature, below 25 °C, in the original packaging to protect them from moisture and light. Keep the product out of reach of children and avoid storing in bathrooms or other humid environments.

Inpalix is taken orally, usually once daily, with or without food, as directed by the prescribing clinician. The tablet should be swallowed whole with a glass of water and not chewed or crushed unless specifically instructed by a healthcare professional.

The most serious adverse reactions to monitor include neuroleptic malignant syndrome, tardive dyskinesia, seizures, agranulocytosis, and myocarditis. Patients should be educated to seek immediate medical attention if they experience high fever, muscle rigidity, uncontrolled movements, signs of infection, or cardiac symptoms.

Inpalix is contraindicated in patients with known hypersensitivity to paliperidone or any component of the formulation. Caution is advised for individuals with severe cardiovascular disease, uncontrolled diabetes, a history of seizures, or those taking other QT‑prolonging drugs. Use in elderly patients with dementia‑related psychosis is generally avoided due to increased mortality risk.